Compare TransMedics Group Inc (TMDX) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Toro Company (The) Common Stock — how do they compare? TransMedics Group Inc trades at $75.02 (market cap $2.62B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.30B). The key difference: Toro Company (The) Common Stock is far larger — about 3.5× TransMedics Group Inc's market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Toro Company (The) Common Stock for 0 Days on average.
| TMDX | TTC | |
|---|---|---|
Market Cap | $2.62B | $9.30B |
Volume | 891,435 | 420,909 |
Sector | Health | Industrials |
52-Week High | $150.42 | $101.76 |
52-Week Low | $61.99 | $67.99 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $3.01B | $10.20B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $79.135, up 1.23% on the day, but faces a bearish technical signal with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 58.69% gross margin and 22.69% net margin, though net income is projected to decline in 2026. Recent news highlights insider buying and CFO appointment, but also ongoing legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but risks include margin pressure from heavy investment and legal overhangs. Upside hinges on execution against guidance, while downside is cushioned by solid cash flow and institutional support.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
